


Semaglutide

Chemical Properties

CAS No. :	910463-68-2
Formula:	C187H291N45O59
Molecular Weight:	4114
Storage:	Keep away from moisture,Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).
Targets(IC50)	Apoptosis,Bcl-2 Family,Autophagy,Glucagon Receptor,IGF-1R,p38 MAPK

Solubility Information

Solubility	H2O: 10 mg/mL (2.43 mM),when pH is adjusted to 14 with NaOH. Sonication and heating are recommended. H2O: insoluble DMSO: 50 mg/mL (12.15 mM),Sonication is recommended. H2O: 5 mg/mL (1.22 mM),when pH is adjusted to 1 with HCl. Sonication and heating are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.2431 mL	1.2154 mL	2.4307 mL
5 mM	0.0486 mL	0.2431 mL	0.4861 mL
10 mM	0.0243 mL	0.1215 mL	0.2431 mL
50 mM	0.0049 mL	0.0243 mL	0.0486 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Dhillon S, et al. Semaglutide: First Global Approval. *Drugs*. 2018 Feb;78(2):275-284.

Wang B, Zhu X, Yu S, et al. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice. *Biochemical and Biophysical Research Communications*. 2024: 150170.

Stoicovy R A, Cora N, Perez A, et al. Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor's anti-inflammatory effects. *Inflammation Research*. 2024: 1-14.

Goldenberg R M , Oren S . Semaglutide: Review and Place in Therapy for Adults with Type 2 Diabetes[J]. *Canadian Journal of Diabetes*, 2018:S1499267118301096-.

Liping Z , Lingyu Z , Lin L , et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model[J]. *Neuropeptides*, 2018:S0143417918300684-.

Rakhat Y, et al. Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice. *Nutrients*. 2023 Aug 28;15(17):3765.

Pontes-da-Silva, R.M., et al. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. *Int J Obes* 46, 21-29 (2022).

Withaar, C, et al. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF. *J Am Coll Cardiol Basic Trans Science*. 2023 Oct, 8 (10) 1298-1314.

Rakipovski G, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE^{-/-} and LDLr^{-/-} Mice by a Mechanism That Includes Inflammatory Pathways. *JACC Basic Transl Sci*. 2018 Nov 21;3(6):844-857.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481